News and Events

 

7th November - Thank you to everyone who came to see us at the Fertility Show on 5th and 6th November.


Thank you to everyone who came to see us at our stand at the Fertility Show this weekend. We were able to discusss our confidential, speedy and cost-effective dispensing and delivery service for prescriptions from Fertility Clinics across the UK and Europe.


8th August 2016 - Praise for Stork Fertility Service 

 

Newlife IVF Greece is a leading IVF Unit based in Thessaloniki Greece, offering the full range of fertility investigations and treatments not only to Greek patients but internationally to patients coming from all over Europe, USA, Canada and Australia. They have been using the Stork Fertility Service, for their UK patients, since 2015 and their Lab Director and International Patient Manager, Ms Chrysa Karakosta says:

"We have nothing but positive points to make regarding Stork's services. They are efficient, reliable and have always been there to assist us with anything we have requested. My patients are extremely happy with their services and impressed by both their low cost and top quality customer services. I would recommend them to any clinician or patient who wants to be 100% certain about the quality of medications they receive at home."

Newlife IVF Greece website: www.newlife-ivf.co.uk

1st June 2016- Class I medical device status for Biodose ConnectTM


Quantum Pharma Plc (AIM: QP.), the growing, service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, is pleased to announce that the Grou

p's innovative telemedicine technology, Biodose Connect™ ("the device") has successfully completed formal validation testing and now has Class I medical device status. Quantum can now implement its commercialisation strategy for the device.

The Class I medical device status of Biodose Connect™ means that it now has CE mark authorisation. The process is governed by the Medicines and Healthcare products Regulatory Agency (MHRA), the UK healthcare regulatory authority.

Biodose Connect™ is now ready for use in live patient settings, allowing the patient, carer, doctor or pharmacist to be alerted by remote monitoring if medicines are not taken as prescribed, with the aim of reducing the costs of poor medication adherence to both the NHS and social care fund holders.

The Quantum Board believes this is an exciting development that presents healthcare professionals with an opportunity to remotely monitor patients and to gather empirical data on adherence to the relevant prescription regime for their medication. It is estimated that between a third and half of all medicines prescribed for long-term conditions are not taken as recommended with an estimated cost of waste medication alone of around £100m per year, excluding any associated social or healthcare costs of not achieving the intended health outcomes from treatment1. A report published by the Department of Health said that medication errors contributed to 5 to 8% of hospital admissions in the UK 2.

Quantum is now able to move forward with its commercialisation strategy for this device, which will be branded as "Biodose Connect™ by Vaica". Quantum has been working with Vaica Medical Ltd, a leader in the medical adherence industry, to develop the device since November 2014. Vaica has expertise in developing devices and associated IT to support patients with their adherence and Biodose Connect™ works in conjunction with Vaica's software and further IT applications developed within the Quantum Group.

There will be an initial soft launch of Biodose Connect™ by Vaica to the private pay market through selected pharmacies that are part of a national pharmacy chain. Quantum is also planning services to independent pharmacies on a regional basis. The product's use will then be extended to trials with Clinical Commissioning Groups (CCGs) which it is hoped will lead to funded services and in time to services funded by large pharmaceutical companies.

Biodose Connect™ is an extension of Biodose® that supports the delivery of medicines with real-time information delivered electronically to carers and clinicians about their patients' adherence to their medication regime. Biodose® consists of a tray, 28 medicine pods and a seal, used to arrange medication in a patient specific format. It is currently used by around 50,000 patients across the UK and Ireland in either a care home or domiciliary care and transforms medication management in these settings. It is the only medication delivery system on the market that accommodates both liquid and solid doses.

Andrew Scaife, Chief Executive of Quantum Pharma Plc, commented: "We are delighted that our Biodose Connect™ device now has Class I medical device status and we can start to commercialise it. It is an exciting product that we believe will provide a huge benefit to the NHS, social care providers and pharmaceutical companies, not only by reducing the burden created by medication non-adherence, but also in allowing patients to be treated at home. We look forward to bringing Biodose Connect™ ®to the market and showcasing its strong benefits."


Footnotes

1) Medicines Adherence: Involving patients in decisions about prescribed medicines and supporting adherence (CG76) Jan 2009 NICE http://publications.nice.org.uk/medicines-adherence-cg76

2) Exploring the costs of unsafe care in the NHS. A Report prepared for the Department of Health. Frontier Economics Oct 2014 http://www.frontier-economics.com/documents/2014/10/exploring-the-costs-of-unsafe-care-in-the-nhs-frontier-report-2-2-2-2.pdf


1st July 2014- Distribution Service for Ferring Pharmaceuticals Limited

 

On the 1st July the Stork Fertility Service, part of Biodose Services, commenced the production and distribution of Menopur Administration Kits on behalf of Ferring Pharmaceuticals

Under the new agreement Stork will distribute kits to hospitals, clinics and pharmacies across the UK.

Biodose Services Managing Director, Ian Pearce says: “We are delighted that Ferring Pharmaceuticals has entrusted us with this service. This is a great endorsement of our Stork Fertility Service.”

 


 


16th April 2014 - Centre for Reproduction & Gynaecology Wales praises Stork Service

 

The CRGW was the first Fertility Centre to use the Stork Fertility Service and the feedback has been excellent.

Mr H Tejura, CRGW Director says: “At CRGW we have exclusively used the Stork Fertility Service since beginning of March 14, during which time they have provided an excellent, efficient and totally reliable service. Homecare supply of medication is a vital component of the service we offer and the Stork service reflects the quality values and patient experience we demand for our clients. 

I can confidently recommend the Stork Fertility Service as experts in their field, delivering quality, reliability, and true customer service.”

We can offer a service that you can trust. To find out more about Stork, get in touch 

 

10th March 2014 - The Stork has landed!

Following the launch of the Stork Fertility Service last month, we have provided our service to our first group of patients. Three UK fertility centres are now using the service and the feedback from the centres and their patients has been very positive.
 


1st Feb 2014 - Stork Fertility Service Launched

Biodose Services is proud to announce the launch of the Stork Fertility Service, a new generation of fertility homecare. Our team at Biodose Services has 75+ years’ experience in providing homecare services to fertility clinics and their patients. We have invested this experience in developing a premium service with excellent customer care at its heart. 

We can offer a service that you can trust. To find out more about Stork, get in touch